Cargando…

Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer

OBJECTIVE: The aim of this optimization study was to minimize the acquisition time of (68)Ga-HBED-CC-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with local and metastatic prostate cancer (PCa) to obtain a sufficient image quality and quantification accuracy wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lütje, Susanne, Blex, Sebastian, Gomez, Benedikt, Schaarschmidt, Benedikt M., Umutlu, Lale, Forsting, Michael, Jentzen, Walter, Bockisch, Andreas, Poeppel, Thorsten D., Wetter, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068705/
https://www.ncbi.nlm.nih.gov/pubmed/27755548
http://dx.doi.org/10.1371/journal.pone.0164392
_version_ 1782460824449712128
author Lütje, Susanne
Blex, Sebastian
Gomez, Benedikt
Schaarschmidt, Benedikt M.
Umutlu, Lale
Forsting, Michael
Jentzen, Walter
Bockisch, Andreas
Poeppel, Thorsten D.
Wetter, Axel
author_facet Lütje, Susanne
Blex, Sebastian
Gomez, Benedikt
Schaarschmidt, Benedikt M.
Umutlu, Lale
Forsting, Michael
Jentzen, Walter
Bockisch, Andreas
Poeppel, Thorsten D.
Wetter, Axel
author_sort Lütje, Susanne
collection PubMed
description OBJECTIVE: The aim of this optimization study was to minimize the acquisition time of (68)Ga-HBED-CC-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with local and metastatic prostate cancer (PCa) to obtain a sufficient image quality and quantification accuracy without any appreciable loss. METHODS: Twenty patients with PCa were administered intravenously with the (68)Ga-HBED-CC-PSMA ligand (mean activity 99 MBq/patient, range 76–148 MBq) and subsequently underwent PET/MRI at, on average, 168 min (range 77–320 min) after injection. PET and MR imaging data were acquired simultaneously. PET acquisition was performed in list mode and PET images were reconstructed at different time intervals (1, 2, 4, 6, 8, and 10 min). Data were analyzed regarding radiotracer uptake in tumors and muscle tissue and PET image quality. Tumor uptake was quantified in terms of the maximum and mean standardized uptake value (SUV(max), SUV(mean)) within a spherical volume of interest (VOI). Reference VOIs were drawn in the gluteus maximus muscle on the right side. PET image quality was evaluated by experienced nuclear physicians/radiologists using a five-point ordinal scale from 5–1 (excellent—insufficient). RESULTS: Lesion detectability linearly increased with increasing acquisition times, reaching its maximum at PET acquisition times of 4 min. At this image acquisition time, tumor lesions in 19/20 (95%) patients were detected. PET image quality showed a positive correlation with increasing acquisition time, reaching a plateau at 4–6 min image acquisition. Both SUV(max) and SUV(mean) correlated inversely with acquisition time and reached a plateau at acquisition times after 4 min. CONCLUSION: In the applied image acquisition settings, the optimal acquisition time of (68)Ga-PSMA-ligand PET/MRI in patients with local and metastatic PCa was identified to be 4 min per bed position. At this acquisition time, PET image quality and lesion detectability reach a maximum while SUV(max) and SUV(mean) do not change significantly beyond this time point.
format Online
Article
Text
id pubmed-5068705
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50687052016-10-27 Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer Lütje, Susanne Blex, Sebastian Gomez, Benedikt Schaarschmidt, Benedikt M. Umutlu, Lale Forsting, Michael Jentzen, Walter Bockisch, Andreas Poeppel, Thorsten D. Wetter, Axel PLoS One Research Article OBJECTIVE: The aim of this optimization study was to minimize the acquisition time of (68)Ga-HBED-CC-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with local and metastatic prostate cancer (PCa) to obtain a sufficient image quality and quantification accuracy without any appreciable loss. METHODS: Twenty patients with PCa were administered intravenously with the (68)Ga-HBED-CC-PSMA ligand (mean activity 99 MBq/patient, range 76–148 MBq) and subsequently underwent PET/MRI at, on average, 168 min (range 77–320 min) after injection. PET and MR imaging data were acquired simultaneously. PET acquisition was performed in list mode and PET images were reconstructed at different time intervals (1, 2, 4, 6, 8, and 10 min). Data were analyzed regarding radiotracer uptake in tumors and muscle tissue and PET image quality. Tumor uptake was quantified in terms of the maximum and mean standardized uptake value (SUV(max), SUV(mean)) within a spherical volume of interest (VOI). Reference VOIs were drawn in the gluteus maximus muscle on the right side. PET image quality was evaluated by experienced nuclear physicians/radiologists using a five-point ordinal scale from 5–1 (excellent—insufficient). RESULTS: Lesion detectability linearly increased with increasing acquisition times, reaching its maximum at PET acquisition times of 4 min. At this image acquisition time, tumor lesions in 19/20 (95%) patients were detected. PET image quality showed a positive correlation with increasing acquisition time, reaching a plateau at 4–6 min image acquisition. Both SUV(max) and SUV(mean) correlated inversely with acquisition time and reached a plateau at acquisition times after 4 min. CONCLUSION: In the applied image acquisition settings, the optimal acquisition time of (68)Ga-PSMA-ligand PET/MRI in patients with local and metastatic PCa was identified to be 4 min per bed position. At this acquisition time, PET image quality and lesion detectability reach a maximum while SUV(max) and SUV(mean) do not change significantly beyond this time point. Public Library of Science 2016-10-18 /pmc/articles/PMC5068705/ /pubmed/27755548 http://dx.doi.org/10.1371/journal.pone.0164392 Text en © 2016 Lütje et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lütje, Susanne
Blex, Sebastian
Gomez, Benedikt
Schaarschmidt, Benedikt M.
Umutlu, Lale
Forsting, Michael
Jentzen, Walter
Bockisch, Andreas
Poeppel, Thorsten D.
Wetter, Axel
Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
title Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
title_full Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
title_fullStr Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
title_full_unstemmed Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
title_short Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
title_sort optimization of acquisition time of (68)ga-psma-ligand pet/mri in patients with local and metastatic prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068705/
https://www.ncbi.nlm.nih.gov/pubmed/27755548
http://dx.doi.org/10.1371/journal.pone.0164392
work_keys_str_mv AT lutjesusanne optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT blexsebastian optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT gomezbenedikt optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT schaarschmidtbenediktm optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT umutlulale optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT forstingmichael optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT jentzenwalter optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT bockischandreas optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT poeppelthorstend optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer
AT wetteraxel optimizationofacquisitiontimeof68gapsmaligandpetmriinpatientswithlocalandmetastaticprostatecancer